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Abstract
Lysophosphatidic acid (LPA) is a bioactive phospholi-
pids and involves in various cellular events, including 
tumor cell migration. In the present study, we inves-
tigated LPA receptor and its transactivation to EGFR 
for cyclooxygenase-2 (COX-2) expression and cell mi-
gration in CAOV-3 ovarian cancer cells. LPA induced 
COX-2 expression in a dose-dependent manner, and 
pretreatment of the cells with pharmacological in-
hibitors of Gi (pertussis toxin), Src (PP2), EGF receptor 
(EGFR) (AG1478), ERK (PD98059) significantly inhi-
bited LPA- induced COX-2 expression. Consistent to 
these results, transfection of the cells with selective 
Src siRNA attenuated COX-2 expression by LPA. LPA 
stimulated CAOV-3 cell migration that was abrogated 
by pharmacological inhibitors and antibody of EP2. 
Higher expression of LPA2 mRNA was observed in 
CAOV-3 cells, and transfection of the cells with a se-
lective LPA2 siRNA significantly inhibited LPA-in-
duced activation of EGFR and ERK, as well as COX-2 
expression. Importantly, LPA2 siRNA also blocked 
LPA-induced ovarian cancer cell migration. Collec-
tively, our results clearly show the significance of LPA2 
and Gi/Src pathway for LPA-induced COX-2 ex-
pression and cell migration that could be a promising 
drug target for ovarian cancer cell metastasis.
Keywords: cell movement; cyclooxygenase-2; lyso-
phosphatidic acid; ovarian neoplasms; proto-onco-
gene proteins pp60 (c-src); receptors, lysophosphati-
dic acid 
Introduction
Ovarian cancer represents the fourth leading cause 
of cancer-related death for women in the Western 
world (Kohn et al., 2003). Main reasons for the low 
survival rate of patients with ovarian cancer are 
caused by lack of effective early detection and 
treatment, as well as the highly metastatic nature 
of the disease. While most solid tumors metas-
tasize through blood vessels or lymphatic nodes, 
ovarian cancer metastasizes through direct disse-
mination from the primary site(s) into the peritoneal 
cavity (Gardner et al., 1995). The bioactive lipid 
lysophosphatidic acid (LPA) is detectable in the 
majority of patients with both early- and late-state 
ovarian cancer, reaching concentrations of 80 μM 
in both the plasma and ascites of ovarian cancer 
patients (Xu et al., 1995; Fang et al., 2000). 
Ovarian cancer cells also produce LPA, thereby 
maintaining an LPA-rich microenvironment (Fang 
et al., 2002). Upon binding to G protein coupled 
plasma membrane receptors (LPA1, LPA2, and 
LPA3), LPA exerts diverse biological effects, inclu-
ding cell proliferation/survival, induction of neurite 
retraction, inhibition of gap junctional communi-
cation, and stimulation of cell motility (Moolenaar et 
al., 1997). More recently, LPA4 (GPR23/P2Y9) (No-
guchi et al., 2003) and LPA5 (Kotarsky et al., 2006; 
Lee et al., 2006) have been identified as a sub-
family of LPA receptors. They are structurally dis-
tinct from other LPA receptors.
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    Recent studies on LPA knockout mice indicate 
that each LPA receptor has distinct function 
(Contos et al., 2002). Furthermore, LPA1 is widely 
expressed in human tissues, while the distribution 
of LPA2 and LPA3 is more restricted (An et al., 
1998; Bandoh et al., 1999). Among LPA receptors, 
LPA2 is aberrantly expressed in various cancer 
cells, including ovarian cancer cells (Fujita et al., 
2003). Therefore, expression of LPA receptor might 
be closely related to the development of various 
cancers. 
    Cyclooxygenase-2 (COX-2) is responsible for 
the synthesis of PGE2 and other prostaglandins 
from arachidonic acid (Cao et al., 2002). Expre-
ssion of COX-2 is elevated in ovarian cancer (Klimp 
et al., 2001), and LPA promotes aggressive beha-
vior in ovarian cancer cells through induction of 
COX-2 expression (Symowicz et al., 2005). Des-
pite the importance of COX-2 in LPA-induced inva-
siveness, the detailed underlying mechanism is re-
mained to be solved. Therefore, we undertook to 
investigate the role of LPA receptors in LPA- indu-
ced COX-2 expression and cell migration and pre-
sent herein strong evidence that LPA2 and Gi/Src 
transactivation to EGFR are responsible for COX-2 
expression and aggressiveness in ovarian cancer 
cells.
Materials and Methods
Reagents 
LPA was purchased from Avanti Polar Lipids (Ala-
baster, AL). Pertussis toxin (Glycerol Solution), 
AG1478, PD98059, and GM6001 were from Cal-
biochem (San Diego, CA). VPC32183, AH6809 and 
AH23848 were from Sigma-Aldrich (St. Louis, MO). 
Antibodies for LPA2, COX-2, EGFR, phospho-ERK, 
phospho-Tyr, EP2, c-Src and ERK were from Santa 
Cruz Biotechnology (Santa Cruz, CA). GAPDH anti-
body was obtained from Lab Frontier (Seoul, Korea). 
Enhanced chemiluminescence reagents and Se-
pharose 4B were from Amersham-Pharmacia Bio-
tech (Piscataway, NJ). LipofectAMINE 2000 was 
obtained from Invitrogen (Carlsbad, CA). All other 
reagents used were of the purest grade available.
Cell culture
CAOV-3, OVCAR-3, PA-1, 2774 and SKOV-3 ovarian 
cancer cells were purchased from the American 
Type Culture Collection (Manassas, VA). The cells 
were maintained in the complete medium that 
consists of RPMI 1640 (CAOV-3, OVCAR-3, 2774  
and SKOV-3) or EMEM (PA-1), supplemented with 
10% FBS in a humidified atmosphere containing 
5% CO2 at 37oC. For experimental purposes, the 
cells (5× 105) were plated in six-well culture 
dishes. After 1 day, the cells were serum starved 
overnight before use.
Reverse transcription-PCR (RT-PCR)
Total cellular RNA (1 μg) isolated from cultured cell 
line was used for reverse transcription. The cDNA 
was then subjected to PCR amplification with pri-
mer sets for COX-2, LPA1, LPA2, LPA3, and 
GAPDH: COX-2 forward, 5'-TGGGAAGCCTTCTC-
TAACCTCTCCT-3'; COX-2 reverse 5'-CTTTGACT-
GTGGGAGGATACATCTC-3'; LPA1 forward, 5'-TA-
GTGGTGGTCATTGTGGTCA-3'; LPA1 reverse, 5'- 
GGCAGAGTTGAATTCAGCAAG-3'; LPA2 forward, 
5'-TGGCCTACCTCTTCCTCATGTTCC-3'; LPA2 re-
verse, 5'-ATTGACCAGTGAGTTGGCCT-3'; LPA3 
forward, 5'-GTCCATAGCAACCTGACCAAA-3'; LPA3 
reverse, 5'-GTTCTCCTGAGAGAAGCAGCA-3', GA-
PDH forward, 5'-CATCTTCCAGGAGCGAGA-3'; 
GAPDH reverse, 5'-CTGCTTCACCACCTTCTTG-
AT-3'. PCR products were analyzed by agarose gel 
electrophoresis and visualized by treatment with 
ethidium bromide, and their intensity was com-
pared using EagleSight Software V. 3.2 (Stra-
tagene, La Jolla, CA).
Immunoblotting
Quiescent cells were treated with 25 μM LPA for 
the indicated period. After solubilizing the cells with 
250 μl of ice-cold buffer (Lee et al., 2005), lysates 
were resolved by 10% SDS-PAGE and transferred 
to PVDF membrane. The membrane was blocked 
at 4oC overnight in a covered container and 
allowed to react with a specific antibody in 1:1,000 
dilution, and detection of specific proteins was 
carried out by enhanced chemiluminescence 
following the manufacturer’s instruction. 
Immunoprecipitation
Lysates containing 200 μg of proteins in extraction 
buffer were incubated with 4 μg/ml anti-EGFR 
antibody at room temperature for 5 h. The immu-
nocomplex was precipitated with protein A Sepha-
rose CL-4B beads (Amersham Biosciences, Pisca-
taway) overnight at 4oC. The beads were washed 
with PBS containing Tween 20, resuspended in 
SDS buffer, and boiled for 5 min. The protein 
samples were then immunoblotted with anti-p-Tyr 
antibody in 1:1,000 dilution.
Estimation of PGE2 and MMP-2
The levels of PGE2 and MMP-2 from the con-
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ditioned media of LPA-treated CAOV-3 cells were 
detected by using the ELISA kits for PGE2 
(Cayman Chemical Company, Ann Arbor, MI) and 
MMP-2 (R&D Systems, Minneapolis, MN) accor-
ding to the manufacturer’s instructions. To mea-
sure the MMP activity, gelatin zymography was 
utilized as described previously (Lakka et al., 
2000). After stimulating with or without LPA for 24 
h, the cells were washed with PBS and incubated 
with fresh serum-free medium. After 24 h, condi-
tioned medium was collected and centrifuged, and 
protein concentrations were determined. Equal 
amounts of protein were subjected to 0.1% gelatin 
SDS-PAGE under nonreducing conditions. Gels 
were washed in 2.5% Triton X-100 and incubated 
overnight in Tris-CaCl2 buffer. The gels were then 
stained with 0.5% Coomassie blue for 1 h and 
destained in 20% methanol and 10% acetic acid. 
The clear bands represent gelatinase activity.
Small interfering RNA (siRNA)
siRNA corresponding to the LPA2 gene was desi-
gned and synthesized by Invitrogen life techno-
logies (Carlsbed, CA). The following sequences 
were used: 5’-UGUGGAACAUGAGGAAGAGGU-
AGGC-3’. siRNA duplexes were used for trans-
fection at a final concentration of 100 pmol. The 
c-Src siRNA was purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA) and is a pool of 4 
Figure 1. LPA induces COX-2 expression through Gi, EGFR and ERK. 
(A) The cells were serum starved overnight, and stimulated with LPA for 
indicated times. Cell lysates were analyzed by immunoblotted against an-
ti-COX-1 or anti-COX-2 antibody. As a control, the lysate of NIH-3T3 cells 
was analyzed in the same gel. (B) The cells were pretreated with or with-
out pharmacological inhibitors of Gi (pertussis toxin), PI3 kinase 
(LY294002 and wortmannin), EGFR (AG1478), ERK (PD98059 and 
U0126), followed by stimulation with indicated concentration of LPA. The 
cell lysates were analyzed by either RT-PCR or immunoblotting. (C) The 
cells were pretreated with or without indicated pharmacological inhibitors, 
followed by stimulation with LPA and the cell migration was analyzed at 
time 0 and 24 h. Results show a representative of three experiments and 
the mean± S.D. of three experiments. #P＜0.05 vs. control, *P＜0.05 
vs. LPA treatment.
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target-specific 20-25 nt siRNAs designed to knock 
down gene expression. Cells were plated onto 
six-well culture dishes a day before the transfection 
and then transiently transfected with Lipofect-
AMINE 2000 according to the manufacture’s ins-
truction. 
Wound healing assay
The cells were grown to confluence in six-well 
plates for 2 days and serum starved overnight. A 
scrape in the form of a cross was made through 
the confluent monolayer with a plastic pipette tip. 
The cells were treated with or without inhibitors, 
followed by LPA treatment. For siRNA experiment, 
the cells were first transfected with or without 
siRNA. Then the confluent cells were serum 
starved overnight, and a scrape was made before 
LPA treatment. Several wounded areas were 
marked for orientation, observed, and then photo-
graphed by phase contrast microscopy at 24 h 
after the scratch.
Statistical analysis
Results are expressed as the mean± S.D. and an 
analysis was done by one-way Student's t-test. 
P-values less than 0.05 were considered statis-
tically significant.
Results
LPA induces COX-2 expression
Ovarian cancer leads to more fatalities than any 
other form of gynecological cancer in the deve-
loped world. As a possible biomarker for ovarian 
cancer cells, LPA enhances tumor cell motility, 
proliferation, angiogenesis, survival, invasion and 
metastasis through LPA receptors (Fang et al., 
2000). It has been recently reported that LPA 
stimulates the expression of COX-2 that promotes 
aggressive behavior in ovarian cancer DOV13 cells 
(Symowicz et al., 2005). To determine the effect of 
LPA on COX-2 expression in our system, the 
serum-starved various ovarian cancer cells were 
stimulated by 25 μM LPA for 3 h, and COX 
expression levels were analyzed by immuno-
blotting (Figure 1A). Among the tested ovarian 
cancer cells, COX-1 expression was not detectable 
even in the presence of LPA. While COX-2 was 
expressed in both CAOV-3 and 2774 cells as the 
basal level, LPA induced COX-2 expression only in 
CAOV-3 cells. Furthermore, LPA induced both 
COX-2 mRNA and protein expression in a dose- 
dependent manner in CAOV-3 cells (Figure 1B). 
Next, we treated CAOV-3 cells with various phar-
macological inhibitors to determine the intracellular 
signaling pathway of COX-2 expression by LPA. 
Induction of COX-2 protein by LPA was completely 
inhibited by pharmacological inhibitors of phospha-
tidylinositide 3-kinase (PI3 kinase, LY294002 and 
wortmannin), ERK (PD98059 and U0126), Gi (per-
tussis toxin) and EGFR (AG1478), suggesting the 
critical roles of PI3 kinase ERK, GI and EGFR for 
COX-2 expression (Figure 1B). To determine the 
effect of LPA on CAOV-3 cell migration, the cells 
were stimulated with or without LPA, and the cell 
migration was measured by wound healing 
analysis. LPA strongly closed the wound after 24 h 
of scratch (Figure 1C). However, LPA-induced cell 
migration was abrogated when the cells were 
pretreated with PD98059 or U0126. Therefore, 
these results clearly show the important role of 
ERK for LPA-induced cell migration in CAOV-3 
cells.
LPA transactivates EGFR through Gi and Src
Although the role of EGFR for LPA-induced COX-2 
expression was previously studied (Symowicz et 
al., 2005), little is known how EGFR is transac-
tivated by LPA receptor in ovarian cancer cells. To 
examine EGFR activation by LPA, CAOV-3 cells 
were treated with pharmacological inhibitors of 
MMP (GM6001) or Src (PP2), followed by stimu-
lation with LPA. LPA-induced phosphorylation of 
EGFR and ERK was significantly inhibited by PP2 
treatment (Figure 2A). In addition, PP2 treatment 
also abrogated COX-2 expression by LPA. However, 
GM6001 treatment did not show any remarkable 
inhibition of EGFR phosphorylation and COX-2 
expression by LPA. These results indicate that Src 
but not MMP pathway is necessary for LPA- 
induced EGFR transactivation and COX-2 expre-
ssion. To confirm the importance of Src on LPA- 
induced COX-2 expression, the cells were trans-
fected with selective c-Src siRNA, and the expre-
ssion of COX-2 was analyzed. As shown in Figure 
2B, LPA-induced COX-2 expression was pro-
foundly inhibited by c-Src siRNA. Next, CAOV-3 
cells were treated with LPA with or without PP2 
and GM6001, and MMP-2 expression and activa-
tion were monitored to substantiate our data 
showing COX-2 expression by LPA independent to 
MMP. As shown in Figure 2C, LPA did not induce 
the expression and activation of MMP-2.
PGE2 is involved in LPA-induced cell migration
One of the underlying mechanisms of COX-2 indu-
ced cell migration is through the production of 
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Figure 2. Src is involved in EGFR transactivation. The cells were pretreated with pharmacological inhibitors of Src (PP2) or MMP (GM6001) for 1 h, fol-
lowed by stimulation with 25 μM LPA. (A) The cell lysates were immunoblotted as described in materials and methods. Anti-p-Tyr antibody was utilized to 
detect P-EGFR, after the cell lysate was immunoprecipitated with EGFR antibody. Results show a representative blot of three experiments and the mean 
± S.D. of three experiments. (B) The cells were transfected with either selective c-Src or negative control siRNA, followed by stimulation with or without 
25 μM LPA. (C) Conditioned media was analyzed by gelatin zymography (upper gel) and ELISA (lower graph) to detect MMP-2 activity and total ex-
pression, respectively. Results show a representative gel and ELISA of three experiments. #P＜ 0.05 vs. control, *P＜ 0.05 vs. LPA treatment.
PGE2, leading to either activation of EGFR 
(Buchanan et al., 2003) or MAPK/ERK (Krysan et 
al., 2005). PGE2 also has been implicated in 
tumorigenesis and tumor progression in several 
cancers (Eberhart et al., 1994; Kargman et al., 
1995; Hida et al., 1998). To test the role of COX-2 
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Figure 3. EP2 is involved in LPA-induced cell migration. (A) The cells were pre-incubated with or without pharmacological inhibitors of COX-2 (100 μM 
NS-398, 50 μM celecoxib), followed by 25 μM LPA stimulation. The cell migration was assessed by wound healing at time 0 h and 24 h. (B) Pre-in-
cubated cells with COX-2 inhibitors were stimulated with LPA, and the amount of PGE2 was assessed by ELISA. (C) The cells were pre-incubated with 
pharmacological inhibitors of EP2 (AH6809), EP4 (AH23848) or anti-EP2 blocking antibody, followed by LPA stimulation. The cell migration was analyzed 
by wound healing at time 0h and 24 h. Results show a representative of five experiments and the mean± S.D. of five experiments. #P＜ 0.05 vs. con-
trol, *P＜ 0.05 vs. LPA treatment.
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Figure 4. LPA2 is responsible for phosphorylation of EGFR and ERK, as well as COX-2 expression. (A) Total RNA of CAOV-3 cells were reverse tran-
scribed and amplified utilizing specific primers for each LPA receptors with LPA or not as described in Materials and methods. (B) The cells were pre-
treated with or without pharmacological inhibitors of LPA1 & LPA3 (VPC32183, Ki16425), followed by stimulation with indicated concentration of LPA. The 
cell lysates were analyzed by immunoblotting. Results show a representative blot of three experiments. (C) The cells were transfected with either LPA2 
specific siRNA or negative control siRNA, followed by stimulation with or without 25 μM LPA. The cell lysates were subject to immunoblotting against each 
antibody. Results show a representative blot of three experiments.
on LPA-induced cell migration, the cells were 
pretreated with COX-2 selective inhibitors. As shown 
in Figure 3A, LPA-induced cell migration was pro-
foundly inhibited by NS-398 and celecoxib, sug-
gesting the importance of COX-2 for LPA-induced 
CAOV-3 cell migration. Next, we determined the 
effect of LPA on PGE2 production. Like other ova-
rian cancer HEY or OVCAR-433 cells (Spinella et 
al., 2004), CAOV-3 cells secrete more than 100 
pg/ml of PGE2 even without any treatment. When 
the cells were stimulated with LPA, PGE2 secretion 
was dramatically increased. However, LPA-induced 
PGE2 production was abrogated in the presence of 
COX-2 inhibitors (Figure 3B). To gain an insight 
whether and which receptor of PGE2 is involved in 
LPA-induced CAOV-3 cell motility, the cells were 
treated with pharmacological antagonist for EP2 
(AH6809) and EP4 (AH23848). As shown in Figure 
3C, pretreatment of the cells with AH6809 but not 
AH23848 significantly inhibited LPA-induced cell 
migration. Furthermore, treatment of the cells with 
anti-EP2 antibody profoundly inhibited LPA-induced 
cell migration. These results suggest the impor-
tance of EP2 receptor of PGE2 for CAOV-3 cell 
migration by LPA.
LPA2 is involved in LPA-induced COX-2 expression
There are at least three types of LPA receptors 
mediating LPA-induced biological phenomenon, 
and their differential expression were reported in 
various cancer cells, including ovarian cancer cells 
(Wang et al., 2007). To examine the mRNA expre-
ssion of these LPA receptors in CAOV-3 cells, 
RT-PCR analysis was utilized with specific LPA 
receptor primers. As shown in Figure 4A, higher 
mRNA expression of LPA2 was observed com-
pared to that of LPA1 and LPA3. To test which type 
of receptor is responsible for LPA-induced COX-2 
expression, the cells were incubated with VPC32183 
or Ki16425 that inhibits LPA1 and LPA3. As shown 
in Figure 4B, VPC32183 and Ki16425 did not 
inhibit LPA-induced COX-2 expression, suggesting 
that LPA1 and LPA3 are not involved in COX-2 
expression by LPA. Next, we determined the role 
of LPA2 on LPA-induced COX-2 expression by 
utilizing LPA2 specific siRNA. Unlike negative 
control siRNA, transfection of LPA2 siRNA 
efficiently reduced the expression of LPA2 protein 
(Figure 4C), indicating the specificity of LPA2 
siRNA. Then, the cells were transfected with LPA2
siRNA, followed by stimulation with LPA. LPA2 
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Figure 5. LPA2 is involved in LPA-induced cell motility. The cells were 
transfected with either LPA2 or negative control siRNA, followed by stim-
ulation with or without 25 μM LPA. Results show a representative of four 
experiments and the mean± S.D. of four experiments. #P＜ 0.05 vs. 
control, *P＜ 0.05 vs. LPA treatment.
siRNA completely blocked LPA-induced COX-2 
protein expression (Figure 4C), suggesting that 
LPA2 is necessary for COX-2 expression by LPA. 
Moreover, transfection of the cells with LPA2 
siRNA inhibited LPA-induced phosphorylation of 
EGFR and ERK that are critical for COX-2 expre-
ssion by LPA. Therefore, these results clearly de-
monstrate the essential roles of LPA2 on activation 
of EGFR and ERK, leading to COX-2 expression. 
LPA2 is responsible for CAOV-3 cell migration
LPA receptors are implicated in the cell motility of 
various types of cells. LPA1 is linked to MC3T3E1 
osteoblast motility (Masiello et al., 2006), while 
LPA2 is involved in RAFTK/PyK2 phosphorylation 
and PC12 cell motility (Park et al., 2006). Since 
LPA2 is overexpressed in CAOV-3 cells and 
involved in COX-2 expression, we tested the role 
of LPA2 on cell migration. The cells were trans-
fected with either LPA2 specific siRNA or negative 
control siRNA, followed by stimulation with or 
without LPA. Transfection of the cells with LPA2 
siRNA but not negative control siRNA abrogated 
LPA-induced cell migration, indicating the critical 
role of LPA2 on CAOV-3 cell migration (Figure 5).
Discussion
Tumor cell invasion and metastasis is a complex, 
multi-step process during which tumor cells spread 
from the primary tumor to distant organs (Yang et 
al., 2006). Accumulated clinical and experimental 
evidence indicates that COX-2 is involved in the 
metastatic phenotypes of cancers, including ovarian 
cancer. In the present study, we for the first time 
demonstrate the importance of LPA receptor and 
Gi/Src signaling for LPA-induced EGFR activation, 
COX-2 expression, as well as motility stimulation in 
CAOV-3 ovarian cancer cells.
    There are several signaling pathways for EGFR 
transactivation by LPA receptor. One of them invol-
ves Gi and Src. Pretreatment of the adrenal glome-
rulosa cells with PP2, a Src inhibitor, inhibited 
EGFR transactivation and ERK activation by LPA 
(Shah et al., 2005). Another well-known pathway for 
EGFR transactivation is matrix metalloproteinase 
(MMP) activation by LPA receptor. MMP stimulates 
proteolytic cleavage of transmembrane precursors, 
such as pro-HB-EGF, which subsequently activates 
the EGFR family (Prenzel et al., 1999; Gschwind et 
al., 2002). In human bronchial epithelial cells, 
activation of Lyn and MMP but not Src are required 
for EGFR transactivation by LPA (Zhao et al., 
2006). In the present study, we showed that Src, 
but not MMP pathway is involved in LPA-induced 
EGFR activation and COX-2 expression. Pretreat-
ment of the cells with PP2 abolished phospho-
rylation of EGFR and ERK, as well as COX-2 
expression by LPA (Figure 2A). Furthermore, 
LPA-induced COX-2 expression was also signifi-
cantly inhibited by Src siRNA pretreatment. Pre-
vious report claimed that MMP activation for 
proteolytic cleavage of transmembrane precursors 
was a critical step for EGFR activation in human 
colon cancer cells (Shida et al., 2005). This 
difference could be due to the types of cancer cells 
tested. 
    The relative expression of LPA receptor isotypes 
depends on the type of cells. While higher expre-
ssion of LPA-1 was reported in OVCAR-3 cells, 
LPA3 is the major receptor type in SKOV-3 cells 
(Park et al., 2007). In the present study, we 
showed that LPA2 expression is higher than other 
types of LPA receptor in CAOV-3 cells. These re-
sults are in good accord with previous report (Fang 
et al., 2004). The roles of LPA receptor on cancer 
cell motility are well documented. LPA1 is required 
for the motility of breast, prostate, and melanoma 
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cells (Hama et al., 2004). Human pancreatic 
cancer cells also use LPA1 for LPA-induced cell 
migration (Yamada et al., 2004). However, the LPA 
receptor responsible for LPA-induced ovarian 
cancer cell migration is controversial. While LPA2 
was reported to mediate LPA-induced human 
ovarian cancer cell migration (Xu et al., 2004; 
Symowicz et al., 2005), Sugimoto et al. recently 
claimed that LPA1 is critical for motility stimulation 
by LPA in CHO cells (2006). Furthermore, little is 
known which LPA receptor is responsible for 
COX-2 expression to stimulate ovarian cancer cell 
motility. We therefore determined the receptor 
responsible for LPA-induced COX-2 expression 
and motility stimulation. Our data clearly demons-
trate that LPA2 is critical for COX-2 expression, 
leading to ovarian cancer cell motility stimulation 
by LPA. First, much higher expression of LPA2 
than LPA1 and LPA3 was shown in CAOV-3 cells. 
Second, transfection of the cells with LPA2 selec-
tive siRNA inhibited phosphorylation of ERK and 
EGFR, as well as COX-2 expression. Finally and 
most importantly, transfection of selective LPA2 
siRNA abolished motility stimulation by LPA.
    In conclusion, our data clearly show that LPA 
stimulates COX-2 expression and cell motility 
through LPA2/Gi/Src/EGFR/ERK signaling cascade 
in ovarian cancer cells. Our results will help to 
understand the molecular mechanism for LPA- 
induced motility and useful approach for inhibition 
of motility in ovarian cancer progression.
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